The purpose of this study is to find out the effect of Dexmedetomidine for treatment of sleep deprivation, pain relief and postoperative recovery on middle-aged and elderly Patients with Gastric Cancer.
Patients were randomized to receive sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h (DEX group) or sufentanil 0.05ug/kg/h + saline (control group) for 48h. The primary outcome was the total sleep time during the first three days after surgery. The secondary outcomes included pain score, daily sufentanil consumption, time to functional recovery, length of hospital stay and side effects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
50
sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
sleep time
total sleep time during the first three days after surgery
Time frame: during the first three days after surgery
pain score
pain score measure
Time frame: during the first three days after surgery
daily sufentanil consumption
daily sufentanil consumption
Time frame: during the first three days after surgery
functional recovery
time to functional recovery
Time frame: during the first three days after surgery
length of hospital stay
length of hospital stay
Time frame: during the first three days after surgery
side effects
lethargy and mental sluggishness
Time frame: during the first three days after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.